Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management of fatty liver in the clinical setting. Excess weight subjects carry a greater metabolic risk even before exhibiting pathological patterns, including diabetes. We characterized the cross-sectional relationship between routine circulating biomarkers and NAFLD in a large sample of diabetes-free subjects with overweight or obesity, to elucidate any independent relationship. A population sample of 1232 consecutive subjects with a body mass index of at least 25 kg/m(2), not receiving any drug or supplemental therapy, was studied. Clinical data and routine biochemistry were analyzed. NAFLD was defined using the validated fatty liver index (FLI), classifying...
Comprehensive screening for non-alcoholic fatty liver disease (NAFLD) may help prompt clinical manag...
The relationship between rising body mass index (BMI) and prospective risk of non-alcoholic fatty li...
Abstract Aims/Introduction We aimed to determine whether mean and visit‐to‐visit glycated hemoglobin...
Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management of fatty ...
Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management of fatty ...
Background and aimsIt is not known whether non alcoholic fatty liver disease (NAFLD) is a risk facto...
Aims:To investigate the association between overweight/obesity and fatty liver index (FLI) on the od...
Background:<p></p>With obesity on the rise, non alcoholic fatty liver disease (NAFLD) is...
OBJECTIVE: Follow-up studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated...
Diabetics have a higher risk of developing nonalcoholic fatty liver disease (NAFLD) and associated c...
Nonalcoholic fatty liver disease (NAFLD) is the commonest liver condition in the world, accounting f...
Background and Aim:: The magnitude of the risk of incident type 2 diabetes (T2D) and metabolic syndr...
ObjectiveNon-alcoholic fatty liver disease (NAFLD) is prevalent in patients with type 2 diabetes. He...
BACKGROUND: Obesity and type 2 diabetes are well-known risk factors for the development of nonalcoho...
Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with Type 2 diabetes (T2DM) an...
Comprehensive screening for non-alcoholic fatty liver disease (NAFLD) may help prompt clinical manag...
The relationship between rising body mass index (BMI) and prospective risk of non-alcoholic fatty li...
Abstract Aims/Introduction We aimed to determine whether mean and visit‐to‐visit glycated hemoglobin...
Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management of fatty ...
Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management of fatty ...
Background and aimsIt is not known whether non alcoholic fatty liver disease (NAFLD) is a risk facto...
Aims:To investigate the association between overweight/obesity and fatty liver index (FLI) on the od...
Background:<p></p>With obesity on the rise, non alcoholic fatty liver disease (NAFLD) is...
OBJECTIVE: Follow-up studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated...
Diabetics have a higher risk of developing nonalcoholic fatty liver disease (NAFLD) and associated c...
Nonalcoholic fatty liver disease (NAFLD) is the commonest liver condition in the world, accounting f...
Background and Aim:: The magnitude of the risk of incident type 2 diabetes (T2D) and metabolic syndr...
ObjectiveNon-alcoholic fatty liver disease (NAFLD) is prevalent in patients with type 2 diabetes. He...
BACKGROUND: Obesity and type 2 diabetes are well-known risk factors for the development of nonalcoho...
Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with Type 2 diabetes (T2DM) an...
Comprehensive screening for non-alcoholic fatty liver disease (NAFLD) may help prompt clinical manag...
The relationship between rising body mass index (BMI) and prospective risk of non-alcoholic fatty li...
Abstract Aims/Introduction We aimed to determine whether mean and visit‐to‐visit glycated hemoglobin...